Evaluating the Role of Visfatin and Metabolic Markers in Osteoarthritis Cases with Diabetes Mellitus in Sulaimani City, Kurdistan Region, Iraq
DOI:
https://doi.org/10.24237/04.02.790Abstract
It was demonstrated that neuropathy was due to impaired glucose control levels in the blood, which caused pain due to osteoarthritis. Early, undetectable levels of biological alteration are characteristic of both osteoarthritis and diabetes mellitus, which are chronic diseases. This study was conducted to investigate serum visfatin levels and their association with parameters in patients with osteoarthritis. Sixty-eight patients with diabetes mellitus and osteoarthritis are included in the present research to examine the effect of visfatin and associated clinical markers in these cases. Twenty healthy control volunteers were used to compare the outcomes. Accurate kits were used to determine visfatin and related parameters. The present study's findings revealed increases in visfatin, glucose, HbA1c, and insulin resistance levels among patients, while insulin levels decreased. It appears that visfatin has been established to have a physiological effect on osteoarthritis in patients suffering from type II diabetes mellitus.
Downloads
References
[1] Gómez, R., Villalvilla, A., Largo, R., Gualillo, O., and Herrero-Beaumont, G., ‘TLR4 signalling in osteoarthritis—finding targets for candidate DMOADs’, Nature Reviews Rheumatology,vol. 11,no. 3, pp. 159-170, 2015, https://doi.org/10.1038/nrrheum.2014.209
[2] Ratajczak-Pawlowska, A.E., Szymczak-Tomczak, A., Hryhorowicz, S., Zawada, A., Skoracka, K., Rychter, A.M., Skrzypczak-Zielinska, M., Slomski, R., Dobrowolska, A., and Krela-Kazmierczak, I., ‘Relationship of visfatin with obesity and osteoporosis in patients with inflammatory bowel disease: a narrative review’, Frontiers in Immunology,vol. 16, 2025. https://doi.org/10.3389/fimmu.2025.1533955
[3] Kohn, R., Saxena, S., Levav, I., and Saraceno, B., ‘The treatment gap in mental health care’, Bulletin of the World Health Organization,vol. 82,no. 11, pp. 858-866, 2004, https://doi.org/10.2471/BLT.03.012948.
[4] Kowalska, I., Karczewska-Kupczewska, M., Adamska, A., Nikolajuk, A., Otziomek, E., and Straczkowski, M., ‘Serum visfatin is differentially regulated by insulin and free fatty acids in healthy men’, The Journal of Clinical Endocrinology & Metabolism,vol. 98,no. 2, pp. E293-E297, 2013, doi:10.1210/jc.2012-2904.
[5] Chang, Y.H., Chang, D.M., Lin, K.C., Shin, S.J., and Lee, Y.J., ‘Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review’, Diabetes Metab Res Rev,vol. 27,no. 6, pp. 515-527, 2011, https://doi.org/10.1002/dmrr.1201.
[6] Veronese, N., Cooper, C., Reginster, J.-Y., Hochberg, M., Branco, J., Bruyere, O., Chapurlat, R., Al-Daghri, N., Dennison, E., and Herrero-Beaumont, G.: ‘Type 2 diabetes mellitus and osteoarthritis’, in Editor (Ed.): ‘Book Type 2 diabetes mellitus and osteoarthritis’ (Elsevier, 2019, edn.), pp. 9-19 doi:10.1016/B978-0-12-813170-7.00002-9.
[7] Uslu, S., Kebapci, N., Kara, M., and Bal, C., ‘Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus’, Exp Ther Med,vol. 4,no. 1, pp. 113-120, 2012, doi:10.3892/etm.2012.557.
[8] Chen, M.-P., Chung, F.-M., Chang, D.-M., Tsai, J.C.-R., Huang, H.-F., Shin, S.-J., and Lee, Y.-J., ‘Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus’, The Journal of Clinical Endocrinology & Metabolism,vol. 91,no. 1, pp. 295-299, 2006, doi:10.1210/jc.2005-1475.
[9] Lago, F., Dieguez, C., Gómez-Reino, J., and Gualillo, O., ‘Adipokines as emerging mediators of immune response and inflammation’, Nature clinical practice Rheumatology,vol. 3,no. 12, pp. 716-724, 2007, doi:10.1038/ncprheum0674.
[10] Dogru, T., Sonmez, A., Tasci, I., Bozoglu, E., Yilmaz, M.I., Genc, H., Erdem, G., Gok, M., Bingol, N., and Kilic, S., ‘Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance’, Diabetes research and clinical practice,vol. 76,no. 1, pp. 24-29, 2007, doi:10.1016/j.diabres.2006.07.024.
[11] Haider, D.G., Pleiner, J., Francesconi, M., Wiesinger, G.n.F., Müller, M., and Wolzt, M., ‘Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes’, The Journal of Clinical Endocrinology & Metabolism,vol. 91,no. 11, pp. 4702-4704, 2006, doi:10.1210/jc.2006-1075.
[12] Ha, C.H., Swearingin, B., and Jeon, Y.K., ‘Relationship of visfatin level to pancreatic endocrine hormone level, HOMA-IR index, and HOMA β-cell index in overweight women who performed hydraulic resistance exercise’, Journal of Physical Therapy Science,vol. 27,no. 9, pp. 2965-2969, 2015, doi:10.1589/jpts.27.2965.
[13] Ikeda, K., Tojo, K., Inada, Y., Takada, Y., Sakamoto, M., Lam, M., Claycomb, W.C., and Tajima, N., ‘Regulation of urocortin I and its related peptide urocortin II by inflammatory and oxidative stresses in HL-1 cardiomyocytes’, J Mol Endocrinol,vol. 42,no. 6, pp. 479-489, 2009, doi:10.1677/JME-08-0151.
[14] Svoboda, P., Krizova, E., Sestakova, S., Vapenkova, K., Knejzlik, Z., Rimpelova, S., Rayova, D., Volfova, N., Krizova, I., and Rumlova, M., ‘Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle–dependent in mammalian cells, and its inhibition slows cell growth’, Journal of Biological Chemistry,vol. 294,no. 22, pp. 8676-8689, 2019, doi:10.1074/jbc.RA118.006505.
[15] Garten, A., Schuster, S., Penke, M., Gorski, T., De Giorgis, T., and Kiess, W., ‘Physiological and pathophysiological roles of NAMPT and NAD metabolism’, Nature Reviews Endocrinology,vol. 11,no. 9, pp. 535-546, 2015, doi:10.1038/nrendo.2015.117.
[16] Revollo, J.R., Grimm, A.A., and Imai, S.-i., ‘The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals’, Current opinion in gastroenterology,vol. 23,no. 2, pp. 164-170, 2007, doi:10.1097/MOG.0b013e328014c77c.
[17] Garten, A., Petzold, S., Barnikol-Oettler, A., Körner, A., Thasler, W., Kratzsch, J., Kiess, W., and Gebhardt, R., ‘Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes’, Biochemical and biophysical research communications,vol. 391,no. 1, pp. 376-381, 2010, doi:10.1016/j.bbrc.2009.11.066.
[18] Li, Y., Zhang, Y., Dorweiler, B., Cui, D., Wang, T., Woo, C.W., Brunkan, C.S., Wolberger, C., Imai, S., and Tabas, I., ‘Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism’, J Biol Chem,vol. 283,no. 50, pp. 34833-34843, 2008, doi:10.1074/jbc.M805866200.
[19] Audrito, V., Messana, V.G., and Deaglio, S., ‘NAMPT and NAPRT: two metabolic enzymes with key roles in inflammation’, Frontiers in Oncology,vol. 10, pp. 358, 2020, doi:10.3389/fonc.2020.00358.
[20] Ognjanovic, S., and Bryant-Greenwood, G.D., ‘Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes’, American Journal of Obstetrics and Gynecology,vol. 187,no. 4, pp. 1051-1058, 2002, doi:10.1067/mob.2002.126295.
[21] Tanaka, M., Nozaki, M., Fukuhara, A., Segawa, K., Aoki, N., Matsuda, M., Komuro, R., and Shimomura, I., ‘Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway’, Biochemical and biophysical research communications,vol. 359,no. 2, pp. 194-201, 2007, doi:10.1016/j.bbrc.2007.05.096.
[22] Kitani, T., Okuno, S., and Fujisawa, H., ‘Growth phase‐dependent changes in the subcellular localization of pre‐B‐cell colony‐enhancing factor’, FEBS letters,vol. 544,no. 1-3, pp. 74-78, 2003, doi:10.1016/S0014-5793(03)00476-9.
[23] Romacho, T., Villalobos, L.A., Cercas, E., Carraro, R., Sanchez-Ferrer, C.F., and Peiro, C., ‘Visfatin as a novel mediator released by inflamed human endothelial cells’, PLoS One,vol. 8,no. 10, pp. e78283, 2013, doi:10.1371/journal.pone.0078283.
[24] Revollo, J.R., Grimm, A.A., and Imai, S., ‘The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells’, J Biol Chem,vol. 279,no. 49, pp. 50754-50763, 2004, doi:10.1074/jbc.M408388200.
[25] Kim, S.-R., Bae, Y.-H., Bae, S.-K., Choi, K.-S., Yoon, K.-H., Koo, T.H., Jang, H.-O., Yun, I., Kim, K.-W., and Kwon, Y.-G., ‘Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-κB activation in endothelial cells’, Biochimica et Biophysica Acta (BBA)-Molecular Cell Research,vol. 1783,no. 5, pp. 886-895, 2008, doi:10.1016/j.bbamcr.2008.01.004.
[26] Koltai, E., Bori, Z., Chabert, C., Dubouchaud, H., Naito, H., Machida, S., Davies, K.J., Murlasits, Z., Fry, A.C., and Boldogh, I., ‘SIRT1 may play a crucial role in overload‐induced hypertrophy of skeletal muscle’, The Journal of physiology,vol. 595,no. 11, pp. 3361-3376, 2017, doi:10.1113/JP273386.
[27] Wang, W., Hu, Y., Wang, X., Wang, Q., and Deng, H., ‘ROS-mediated 15-hydroxyprostaglandin dehydrogenase degradation via cysteine oxidation promotes NAD+-mediated epithelial-mesenchymal transition’, Cell Chemical Biology,vol. 25,no. 3, pp. 255-261. e254, 2018, doi:10.1016/j.chembiol.2017.12.015.
[28] Zhao, J., Li, Q., Wang, Y., Liu, B., Gui, S., Zheng, Y., and Chen, X., ‘NAMPT improves high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) via the SIRT1–C/EBPβ–STEAP4–NRF2 axis’, Journal of Molecular Cell Biology, pp. mjaf045, 2025, doi:10.1093/jmcb/mjaf045.
[29] Yu, A., and Dang, W., ‘Regulation of stem cell aging by SIRT1–Linking metabolic signaling to epigenetic modifications’, Molecular and cellular endocrinology,vol. 455, pp. 75-82, 2017, doi:10.1016/j.mce.2017.01.024.
[30] Imai, S.-i., and Guarente, L., ‘NAD+ and sirtuins in aging and disease’, Trends in cell biology,vol. 24,no. 8, pp. 464-471, 2014, doi:10.1016/j.tcb.2014.04.002.
[31] Bai, P., ‘Biology of poly (ADP-ribose) polymerases: the factotums of cell maintenance’, Molecular cell,vol. 58,no. 6, pp. 947-958, 2015, doi:10.1016/j.molcel.2015.01.034.
[32] Schett, G., Kleyer, A., Perricone, C., Sahinbegovic, E., Iagnocco, A., Zwerina, J., Lorenzini, R., Aschenbrenner, F., Berenbaum, F., and D’Agostino, M.-A., ‘Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study’, Diabetes care,vol. 36,no. 2, pp. 403-409, 2013, doi:10.2337/dc12-0924.
[33] Guillemin, F., Rat, A., Mazieres, B., Pouchot, J., Fautrel, B., Euller-Ziegler, L., Fardellone, P., Morvan, J., Roux, C., and Verrouil, E., ‘Prevalence of symptomatic hip and knee osteoarthritis: a two-phase population-based survey’, Osteoarthritis and cartilage,vol. 19,no. 11, pp. 1314-1322, 2011, doi:10.1016/j.joca.2011.08.004.
[34] King, K., and Rosenthal, A., ‘The adverse effects of diabetes on osteoarthritis: update on clinical evidence and molecular mechanisms’, Osteoarthritis and cartilage,vol. 23,no. 6, pp. 841-850, 2015, doi:10.1016/j.joca.2015.02.001.
[35] Stenholm, S., Koster, A., Alley, D.E., Visser, M., Maggio, M., Harris, T.B., Egan, J.M., Bandinelli, S., Guralnik, J.M., and Ferrucci, L., ‘Adipocytokines and the metabolic syndrome among older persons with and without obesity: the InCHIANTI study’, Clinical endocrinology,vol. 73,no. 1, pp. 55-65, 2010, doi:10.1111/j.1365-2265.2010.03705.x.
[36] Wang, X., Hunter, D., Xu, J., and Ding, C., ‘Metabolic triggered inflammation in osteoarthritis’, Osteoarthritis and cartilage,vol. 23,no. 1, pp. 22-30, 2015, doi:10.1016/j.joca.2014.10.002.
[37] Berenbaum, F., ‘Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype’, Postgraduate medical journal,vol. 88,no. 1038, pp. 240-242, 2012, doi:10.1136/postgradmedj-2011-130202.
[38] Chuah, Y.K., Basir, R., Talib, H., Tie, T.H., and Nordin, N., ‘Receptor for advanced glycation end products and its involvement in inflammatory diseases’, International journal of inflammation,vol. 2013,no. 1, pp. 403460, 2013, doi:10.1155/2013/403460.
[39] Courties, A., and Sellam, J., ‘Osteoarthritis and type 2 diabetes mellitus: what are the links?’, Diabetes research and clinical practice,vol. 122, pp. 198-206, 2016, doi:10.1016/j.diabres.2016.10.012.
[40] Robinson, W.H., Lepus, C.M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T.M., and Sokolove, J., ‘Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis’, Nature Reviews Rheumatology,vol. 12,no. 10, pp. 580-592, 2016, doi:10.1038/nrrheum.2016.136.
[41] Franco-Trepat, E., Guillán-Fresco, M., Alonso-Pérez, A., Jorge-Mora, A., Francisco, V., Gualillo, O., and Gómez, R., ‘Visfatin connection: present and future in osteoarthritis and osteoporosis’, Journal of clinical medicine,vol. 8,no. 8, pp. 1178, 2019, doi:10.3390/jcm8081178.
[42] Ogurtsova, K., Guariguata, L., Barengo, N.C., Ruiz, P.L.-D., Sacre, J.W., Karuranga, S., Sun, H., Boyko, E.J., and Magliano, D.J., ‘IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021’, Diabetes research and clinical practice,vol. 183, pp. 109118, 2022, doi:10.1016/j.diabres.2021.109118.
[43] Frier, B., Ashby, J., Nairn, I., and Baird, J., ‘Plasma insulin, C-peptide and glucagon concentrations in patients with insulin-independent diabetes treated with chlorpropamide’, Diabete & Metabolisme,vol. 7,no. 1, pp. 45-49, 1981, doi:10.1016/S1262-3636(81)80040-0.
[44] Barham, D., and Trinder, P., ‘An improved colour reagent for the determination of blood glucose by the oxidase system’, Analyst,vol. 97,no. 1151, pp. 142-145, 1972, doi:10.1039/AN9729700142.
[45] Busso, N., Karababa, M., Nobile, M., Rolaz, A., Van Gool, F., Galli, M., Leo, O., So, A., and De Smedt, T., ‘Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD’, PloS one,vol. 3,no. 5, pp. e2267, 2008, doi:10.1371/journal.pone.0002267.
[46] Romacho, T., Sánchez-Ferrer, C.F., and Peiró, C., ‘Visfatin/Nampt: an adipokine with cardiovascular impact’, Mediators of inflammation,vol. 2013,no. 1, pp. 946427, 2013, doi:10.1155/2013/946427.
[47] Stephens, J.M., and Vidal-Puig, A.J., ‘An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity’, Current opinion in lipidology,vol. 17,no. 2, pp. 128-131, 2006, doi:10.1097/01.mol.0000217890.45646.9a.
[48] Sommer, G., Garten, A., Petzold, S., Beck-Sickinger, A.G., Blüher, M., Stumvoll, M., and Fasshauer, M., ‘Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine’, Clinical Science,vol. 115,no. 1, pp. 13-23, 2008, https://doi.org/10.1042/CS20070353.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 CC BY 4.0
This work is licensed under a Creative Commons Attribution 4.0 International License.
